This inventor holds 1 USPTO granted patent. Top assignee: G.d. Searle & Company. Active years: 1989.
Company Filing History:
Years Active: 1989
Title: Christopher P Chengelis: Innovator in Triazolopyrimidine Diuretics
Introduction
Christopher P Chengelis is a notable inventor based in Chicago, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds that exhibit improved therapeutic profiles.
Latest Patents
Chengelis holds a patent for "Diol metabolites of 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines - 1-(5-Amino-7-phenyl-[1,2,4] triazolo [1,5,c]pyrimidin-8-yl)-1, 2-ethan diol." This innovative glycol is a metabolite of a triazolopyrimidine diuretic, which demonstrates fewer cardiotoxic side effects compared to the parent compound, while maintaining diuretic activity. The invention also encompasses compositions that incorporate the metabolite and methods for its use, including pharmaceutically acceptable salts.
Career Highlights
Chengelis is associated with G.D. Searle & Company, where he has been instrumental in advancing research and development in pharmaceutical innovations. His work has contributed to the understanding and application of diuretic compounds in medical treatments.
Collaborations
Throughout his career, Chengelis has collaborated with esteemed colleagues, including Earl G Burton and Gerald M Walsh. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Christopher P Chengelis is a distinguished inventor whose work in triazolopyrimidine diuretics has the potential to improve patient outcomes through reduced side effects. His contributions to the pharmaceutical industry exemplify the importance of innovation in healthcare.